From: Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Treatments that affect ROS modulation | Combination with immunotherapy | Type of cancer | Molecular targeting | Clinical trial/study project and status | Number of participants | Project status and references |
---|---|---|---|---|---|---|
Oncoxin-Viusid [OV) -75 ml/day suppresses ROS production | Docetaxel + OV Docetaxel + Radiotherapy + OV | Prostate cancer | Targeting ROS | NCT03543670/Phase 2 | 25 | Completed [303] |
Cholecalciferol (Vitamin D3) | Bevacizumab + chemotherapy (Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan) + high-dose vitamin D3 | Advanced or Metastatic Colorectal Cancer (SOLARIS) | Vascular endothelial growth factor (VEGF) inhibition | NCT04094688/Phase 3 | 400 | Ongoing |
Avastin/Sunitinib | Atezolizumab (MPDL3280A) + Avastin Atezolizumab (MPDL3280A) + Sunitinib | Untreated Advanced Renal Cell Carcinoma | Vascular endothelial growth factor (VEGF) inhibition, Receptor tyrosine kinase inhibitor with PD-1 inhibition | NCT02420821/Phase 3 | 915 | Completed [304] |
PARP inhibition suppresses mtROS production | Niraparib + Dostarlimab | Triple negative Breast cancer | PARP inhibition, PD-1 inhibition | NCT04837209/Phase 2 | 32 | Ongoing |
Radiotherapy Chemotherapy | Thoracic radiotherapy 30 Gy/10 fractions carboplatin/etoposide + Durvalumab | Extensive Stage Small-cell Lung Cancer (TRIPLEX) | Topoisomerase II Inhibitors, intra- and inter-strand cross-linkage of DNA molecules within the cell, PD-1 inhibition | NCT05223647/Phase 3 | 302 | Ongoing |
Radiotherapy Chemotherapy | Neoadjuvant radiotherapy (PTV 41.4 Gy in 23 Fractions) +  Paclitaxel (100 mg/m2) and Cisplatin (75 mg/m2) for 5 weeks + Tislelizumab (200 mg per 3 weeks) | Resectable squamous-cell esophageal cancer | Anti-PD-1 therapy | NCT05323890/Phase 2 | 15 | Ongoing |
Radiotherapy Chemotherapy | Stereotactic body radiation therapy (SBRT) + carboplatin + paclitaxel (175 mg/m2) + Durvalumab (1500 mg for every 3 weeks) | Synchronous Oligo-metastatic Non-small cell Lung Cancer | Topoisomerase II Inhibitors, antineoplastic activity, anti-Bcl-2, Anti-PD-1 therapy, | NCT03965468/Phase 2 | 47 | Ongoing |
Chemotherapy | Chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed) + Radiotherapy ( lung dose < 20 Gy and/or a lung V20 < 35%) + Durvalumab | Large Volume Stage III Non-small cell Lung Cancer | Anti-PD-1 therapy, tumor shrinkage | NCT04765709/Phase 2 | 65 | Ongoing |
Radiotherapy Chemotherapy | Cohort B-D & C-FLOT: Surgery/chemotherapy/radiotherapy + Durvalumab •Paclitaxel/Carboplatin + Durvalumab •Oxaliplatin/ 5-fluorouracil (5-FU)/ Leucovorin/ docetaxel + Durvalumab | Oesophageal Cancer | Anti-PD-1 therapy | NCT02735239/Cohort A1 & A2: Phase 1 Cohort B-D & C-FLOT: Phase 2 | 73 | Completed |
Radiotherapy | Radiation-Brachytherapy *brancytherapy (dose = 16 Gy delivered in 2 fractions of 8 Gy per fraction) + Pembrolizumab | Metastatic Esophageal Cancer | Anti-PD-1 therapy | NCT02642809/Phase 1 | 16 | Completed |
Chemotherapy | Paclitaxel (80–100 mg/m2)/ docetaxel (75 mg/m2/ irinotecan 180 mg/m2) +  Pembrolizumab (200 mg) | Esophageal/ Esophagogastric Junction carcinoma | Anti-PD-1/PD-L1 therapy in patients with PD-L1 CPS ≥ 10 | NCT02564263/Phase 3 | 628 | Completed [305] [306] |
Radiotherapy Chemotherapy | Cisplatin and Radiation therapy (30 fractions of 60 Gy in 2 Gy) + Pembrolizumab | Head and neck squamous cell carcinomas (HNSCCs) | Improve locoregional recurrence and distant metastatic rates in high-risk patients | NCT02296684/Phase 2 | 67 | Completed [307] |
PARP inhibition suppresses mtROS production | Niraparib + Pembrolizumab Niraparib + Dostarlimab | Non-small cell Lung Cancer | PARP inhibition, PD-1 inhibition | NCT03308942/Stage 1/Stage 2 | 53 | Completed |